sMICA/sMICB对新诊断的扩散性大B细胞淋巴瘤免疫化疗结果的影响

Sang Eun Yoon1, Sujin Park2, Junhun Cho2

  • 1Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.

Frontiers in oncology
|November 30, 2023
PubMed
概括

在新诊断的扩散性大B细胞淋巴瘤 (ND-DLBCL) 中,可溶性MICA/MICB与预后不佳和不良结果相关. 这些免疫逃避分子影响治疗成功和患者的存活率,突出了它们在瘤进化中的作用.